Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.
Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.
<iframe src="https://hindustansphere.com/embed/cluster/e48a20320dfaf74c82ded7f5299aa249a8aae063" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility"></iframe>
